Latest Regulatory Compliance News

Boom Logistics has announced the continuation of its on-market share buy-back program, aiming to repurchase up to 10% of its shares over the next year as part of its capital management strategy.

Pengana Global Private Credit Trust (ASX – PCX) has announced an $82 million entitlement and shortfall offer at $2.00 per new unit, targeting a 7% annual cash distribution yield. The Trust offers diversified exposure to global private credit funds, primarily in the US and Europe, managed by Pengana Credit with Mercer Consulting as investment consultant.

Nationwide Building Society has confirmed it has largely complied with its post-offer intentions following its acquisition of Virgin Money UK PLC, with a previously disclosed exception.

DGR Global Limited will have its trading suspension lifted on 2 October 2025 following the lodgement of its annual report, marking a key step back to market normalcy.

Audalia Resources has completed a $500,000 placement to a sophisticated investor, issuing 20 million shares to fund critical development stages at its Medcalf Project. The capital injection aims to advance mining design, permits, and approvals while bolstering working capital.

Gold Mountain Limited has voluntarily suspended trading on the ASX pending an announcement that will update the issue price of a recent capital raising placement.

Podium Minerals has announced a major metallurgical breakthrough with a new concentrator flowsheet achieving approximately 80% recovery of key platinum group metals, advancing its Parks Reef Project towards commercialisation.

The ASX has suspended the securities of over 20 companies for failing to lodge their periodic reports on time, signaling regulatory vigilance and raising questions about compliance and market impact.

Memphasys Limited has revised its FY25 financials to reflect a $1.12 million liability linked to uncertain compliance with R&D tax incentive rules, pending a private tax ruling.

PARKD Limited has completed the first tranche of its $0.78 million placement, issuing over 20 million shares at 3 cents each, while launching a Share Purchase Plan for existing shareholders.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.